Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04520152
Other study ID # EFFORT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 23, 2021
Est. completion date November 8, 2023

Study information

Verified date November 2023
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with severe emphysema have limited options for treatment. Current treatments include lung transplant, lung volume reduction surgery or endobronchial lung volume reduction using valves or coils. These options are only available for a small and selected group of patients. The Free Flow Medical Lung Tensioning Device System (LTD) is thought to be the next generation endobronchial treatment for patients with severe emphysema designed to address this unmet need. The LTD is designed to compress the areas of lung parenchyma most damaged by emphysema and to tension surrounding tissue to help restore lung elastic recoil in a similar manner to the lung volume reduction coils.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date November 8, 2023
Est. primary completion date November 8, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of COPD 2. FEV1/FVC = 70% 3. = 40 years of age 4. Post-bronchodilator FEV1 = 45% of predicted 5. Total Lung Capacity > 100% of predicted 6. Residual Volume (RV) > 175% of predicted 7. RV/TLC > 55% 8. Marked dyspnea defined by a score of = 2 on mMRC dyspnea scale of 0-4 9. Emphysema with = 20% destruction (on -950 Hounsfield units) of two potential treatment lobe(s) 10. Stopped smoking for = 6 months prior to entering the study 11. Completed a pulmonary rehabilitation program prior to entering the study and/or have regular (at least once a week) physiotherapy 12. Ability to read, understand and sign the informed consent form Exclusion Criteria: 1. History of recurrent clinically significant respiratory infections and/or COPD exacerbations, defined as = 2 hospitalizations for respiratory infections and/or COPD exacerbations during the year prior to enrolment 2. History of recurrent clinically significant respiratory infections and/or COPD exacerbations, defined as = 3 courses of prednisolone and/or antibiotics for respiratory infections and/or COPD exacerbations during the year prior to enrolment 3. Clinically significant bronchiectasis 4. Severe gas exchange abnormalities defined by PaCO2 > 7.0 kPa (52 mmHg) and/or PaO2 < 7.0 kPa (52 mmHg) (measured on room air) 5. = 10 mg prednisone (or equivalent dose of other corticosteroids) daily 6. Inability to walk > 140 meters in 6 minutes 7. Known pulmonary hypertension defined by right ventricular systolic pressure > 45 mmHg and/or evidence of pulmonary hypertension of right ventricular failure on echocardiogram 8. Significant paraseptal emphysema 9. Giant bullae (>1/3 of lung volume) 10. Medical history of asthma 11. Underwent previous LVRS, lobectomy, pneumonectomy or lung transplant 12. Underwent previous treatment with thermal vapor ablation, AeriSeal, Cryospray, endobronchial coils or endobronchial valves (if still implanted) 13. Evidence of other disease(s) that have a predicted survival of less than one year 14. Inability to tolerate bronchoscopy under general anaesthesia 15. Maintenance antiplatelet (except aspirin/Ascal) or anticoagulant therapy (such as warfarin, Coumadin, heparin, LMWH, DOACs, etc) which cannot be permanently stopped prior to entering the study 16. Pregnant, lactating or plans to become pregnant within the study timeframe 17. Known sensitivity to drugs required to perform bronchoscopy under general anaesthesia 18. Any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments or in the judgment of the investigator would potentially interfere 19. Known Nickel, Titanium, or Nitinol allergy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FreeFlowMedical Lung Tensioning Device
Bronchoscopic lung tensioning device implantation

Locations

Country Name City State
Germany Dept. of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg Heidelberg Baden-Württemberg
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Countries where clinical trial is conducted

Germany,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: type and frequency of device-related and procedure-related AE To evaluate the safety of the LTD in COPD patients with heterogeneous and homogeneous emphysema by evaluating the type and frequency of device-related and procedure-related AE experienced during and following LTD placement through the 3-month visit. 3 months
Primary Procedural succes To evaluate the feasibility of the LTD in COPD patients with heterogeneous and homogeneous emphysema by measuring the frequencies of successful and unsuccessful intended LTD placements. 3 months
Secondary Performance - Quality of Life: St George's Respiratory Questionnaire Change in St George's Respiratory Questionnaire total score 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Not yet recruiting NCT05900544 - Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures N/A
Recruiting NCT06163131 - The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT05854550 - First in Human Study to Assess an Implant to Treat Severe Emphysema N/A
Recruiting NCT05257681 - Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction N/A
Recruiting NCT06068647 - Ultrasound and Respiratory Physiological Signals in Lung Diseases N/A
Recruiting NCT03318406 - Post-Market BTVA Registry
Recruiting NCT04214587 - Biological Investigation of Explanted Endobronchial Lung Valves Study
Completed NCT03205826 - Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia N/A
Recruiting NCT04781582 - LVRS Versus BLVR in Patients With Homogenous Emphysema, CLUB-HE Trial N/A
Recruiting NCT03680495 - Steroid Resistance During COPD Exacerbations With Respiratory Failure
Active, not recruiting NCT04517916 - Zephyr Etude Post-Inscription (French Registry)
Recruiting NCT06249529 - Airway Bypass - Safety and Feasibility Study Early Phase 1
Recruiting NCT06035120 - An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema N/A
Recruiting NCT05567562 - Anti-Platelets in Chronic Obstructive Pulmonary Disease Phase 2
Withdrawn NCT04029077 - Introduction of the Vapor Treatment in The Netherlands
Recruiting NCT03755505 - The Microbiome of Sputum, Urine and Feces in Healthy Persons and Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed NCT03670121 - A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP) N/A